Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,360 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04541225 | Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors | terminated | Phase 1 | 74 | Nuvation Bio Inc.INDUSTRY | 1 | Jul 14, 2023 | clinicaltrials |
| NCT02067741 | CR1447 in Endocrine Responsive-HER2neg and TN-ARpos Breast Cancer | terminated | Phase 2 | 29 | Swiss Cancer InstituteOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT00002668 |
| Pain Control in Patients With Recurrent or Metastatic Breast or Prostate Cancer |
| terminated |
| N/A |
| 13 |
| Eastern Cooperative Oncology GroupNETWORK |
| 4 |
| Jun 22, 2023 |
| clinicaltrials |
| NCT00002934 | Evaluation of Breast Cancer Recurrence Rates Following Surgery in Women With Ductal Carcinoma In Situ | terminated | Phase 2 | 711 | Eastern Cooperative Oncology GroupNETWORK | 2 | Jun 22, 2023 | clinicaltrials |
| NCT03060356 | Autologous T Cells Expressing MET scFv CAR (RNA CART-cMET) | terminated | Early Phase 1 | 77 | University of PennsylvaniaOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT03152929 | Paravertebral Block (PVC) Versus Pectoral Nerve Block (PEC) | terminated | Phase 3 | 89 | Corewell Health WestOTHER | 1 | Jun 6, 2023 | clinicaltrials |
| NCT04305236 | Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer | terminated | Phase 2 | 1 | University of California, IrvineOTHER | 1 | Jun 6, 2023 | clinicaltrials |
| NCT00074269 | Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast Cancer | terminated | Phase 2 | 5 | University of California, San DiegoOTHER | 1 | Jun 5, 2023 | clinicaltrials |
| NCT04942054 | A Study in Patients With Advanced Breast Cancer | terminated | Phase 1 | 9 | Sun Pharma Advanced Research Company LimitedINDUSTRY | 2 | May 22, 2023 | clinicaltrials |
| NCT00597597 | Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer | terminated | Phase 2 | 11 | Rush University Medical CenterOTHER | 1 | May 17, 2023 | clinicaltrials |
| NCT04088435 | Xoft® Intraoperative Radiotherapy (IORT) for Patients With Early-Stage Breast Cancer | terminated | — | 10 | University of LouisvilleOTHER | 1 | May 12, 2023 | clinicaltrials |
| NCT04335006 | A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer. | terminated | Phase 3 | 80 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | May 6, 2023 | clinicaltrials |
| NCT01147016 | Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery | terminated | Phase 2 | 8 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT04396626 | HR+/ HER2- Advanced/ Metastatic Breast Cancer Real World Treatment Patterns and Outcomes | terminated | — | 975 | PfizerINDUSTRY | 1 | Apr 27, 2023 | clinicaltrials |
| NCT03574194 | Methionine-Restricted Diet to Potentiate The Effects of Radiation Therapy | terminated | N/A | 8 | West Virginia UniversityOTHER | 1 | Apr 25, 2023 | clinicaltrials |
| NCT03919214 | Hypertension Management in Cancer Patients | terminated | N/A | 4 | Duke UniversityOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT04189263 | BREADS: Breast Adjuvant Diet Study | terminated | Phase 2 | 6 | Farin AmersiOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT00004935 | Herceptin Followed by Chemotherapy in Treating Women With Metastatic Breast Cancer That Overexpresses HER2 | terminated | Phase 3 | 175 | Swiss Cancer InstituteOTHER | 2 | Apr 18, 2023 | clinicaltrials |
| NCT04489940 | Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer | terminated | Phase 2 | 11 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 6 | Apr 10, 2023 | clinicaltrials |
| NCT02890368 | Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides | terminated | Phase 1 | 56 | PfizerINDUSTRY | 1 | Apr 5, 2023 | clinicaltrials |
| NCT03630601 | Photoacoustic Imaging in Diagnosing Changes in Tumors in Participants With Breast Cancer, Sarcoma, Skin Cancer, or Soft Tissue Malignancy and Healthy Volunteers | terminated | N/A | 7 | Roswell Park Cancer InstituteOTHER | 1 | Mar 31, 2023 | clinicaltrials |
| NCT00323063 | Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer | terminated | Phase 2 | 49 | Rutgers, The State University of New JerseyOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT03354611 | Contrast-Enhanced Cone Beam Breast CT for Diagnostic Breast Imaging | terminated | Phase 2 / Phase 3 | 21 | Koning CorporationINDUSTRY | 1 | Mar 16, 2023 | clinicaltrials |
| NCT00543127 | Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs Anastrozole | terminated | Phase 3 | 870 | Spanish Breast Cancer Research GroupOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT03435640 | REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies(REVEAL) | terminated | Phase 1 / Phase 2 | 64 | Nektar TherapeuticsINDUSTRY | 1 | Mar 8, 2023 | clinicaltrials |
| NCT05228210 | Breast Cancer Self-Efficacy Scale for Partners(BCSES-P) | terminated | — | 25 | Indiana UniversityOTHER | 1 | Mar 7, 2023 | clinicaltrials |
| NCT03137693 | Preoperative Stereotactic Ablative Body Radiotherapy (SABR) for Early-Stage Breast Cancer | terminated | N/A | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 23, 2023 | clinicaltrials |
| NCT03367689 | A Two-stage Simon Design Phase II Study for Non-BRCA MBC Patients With HRD Treated With Olaparib Single Agent(NOBROLA) | terminated | Phase 2 | 7 | MedSIROTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT03510988 | Dedicated Breast PET/MRI in Evaluation of Extent of Disease in Women With Newly Diagnosed Breast Cancer | terminated | N/A | 14 | Weill Medical College of Cornell UniversityOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT03931551 | Olaparib+Trastuzumab in HER2[+],Breast Cancer Susceptibility Gene (BRCA) Mutated Advanced Breast Cancer(OPHELIA) | terminated | Phase 2 | 5 | MedSIROTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT02834247 | A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors | terminated | Phase 1 | 41 | Calithera Biosciences, IncINDUSTRY | 4 | Feb 8, 2023 | clinicaltrials |
| NCT02658812 | Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery | terminated | Phase 2 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 25, 2023 | clinicaltrials |
| NCT02393248 | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | terminated | Phase 1 / Phase 2 | 201 | Incyte CorporationINDUSTRY | 2 | Jan 6, 2023 | clinicaltrials |
| NCT03636776 | Quality of Life and Psychological Vulnerability in Patients With RH+ Metastatic Breast Cancer(EPOCA) | terminated | N/A | 60 | Institut Cancerologie de l'OuestOTHER | 1 | Dec 29, 2022 | clinicaltrials |
| NCT01022138 | Laboratory-Treated T Cells After Second-Line Chemotherapy in Treating Patients With HER2/Neu-Negative Metastatic Breast Cancer | terminated | Phase 2 | 43 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Dec 23, 2022 | clinicaltrials |
| NCT02867644 | Conversational Hypnosis in Women Undergoing Imaging for Breast Cancer(HYCOREMA) | terminated | N/A | 171 | Institut de Cancérologie de LorraineOTHER | 1 | Dec 20, 2022 | clinicaltrials |
| NCT02229149 | Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer | terminated | Phase 2 | 33 | US Oncology ResearchINDUSTRY | 1 | Dec 2, 2022 | clinicaltrials |
| NCT03386162 | SAFIR-PI3K A Phase II Randomized Maintenance Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy in PIK3CA Mutated Advanced Breast Cancer(SAFIR-PI3K) | terminated | Phase 2 | 31 | UNICANCEROTHER | 1 | Nov 28, 2022 | clinicaltrials |
| NCT01905592 | A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients(BRAVO) | terminated | Phase 3 | 216 | Tesaro, Inc.INDUSTRY | 14 | Nov 15, 2022 | clinicaltrials |
| NCT02124902 | Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity | terminated | Phase 2 | 148 | Washington University School of MedicineOTHER | 1 | Nov 7, 2022 | clinicaltrials |
| NCT02474173 | Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer | terminated | Phase 1 | 31 | National Cancer Institute (NCI)NIH | 1 | Nov 4, 2022 | clinicaltrials |
| NCT01649505 | Fibrin Sealant in Preventing Fluid Build Up During Surgery in Patients Undergoing Breast Reconstruction | terminated | N/A | 2 | OHSU Knight Cancer InstituteOTHER | 1 | Nov 2, 2022 | clinicaltrials |
| NCT03579472 | M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer | terminated | Phase 1 | 38 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2022 | clinicaltrials |
| NCT04142060 | Targeting the PAM50 Her2-Enriched Phenotype With Enzalutamide in Hormone Receptor-Positive/Her2-Negative Metastatic BC(ARIANNA) | terminated | Phase 2 | 34 | SOLTI Breast Cancer Research GroupOTHER | 1 | Oct 28, 2022 | clinicaltrials |
| NCT04460430 | Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer(NEREA) | terminated | Phase 2 | 12 | SOLTI Breast Cancer Research GroupOTHER | 2 | Oct 25, 2022 | clinicaltrials |
| NCT02688166 | Cardiac MRI Biomarker Testing (GCC 1618) | terminated | — | 6 | University of Maryland, BaltimoreOTHER | 1 | Oct 13, 2022 | clinicaltrials |
| NCT02913729 | Pre- Versus Postoperative Accelerated Partial Breast Irradiation(PAPBI-2) | terminated | N/A | 65 | The Netherlands Cancer InstituteOTHER | 4 | Sep 29, 2022 | clinicaltrials |
| NCT03128619 | Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer | terminated | Phase 1 | 10 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Sep 26, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Jul 14, 2023source: clinicaltrials